Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial

Published:2018-02-09 Issue:5 Volume:33 Page:783-794
ISSN:0884-0431
Container-title:Journal of Bone and Mineral Research
language:en
Short-container-title:J Bone Miner Res

Author:

Geusens Piet¹,Marin Fernando²,Kendler David L³,Russo Luis A⁴,Zerbini Cristiano AF⁵,Minisola Salvatore⁶,Body Jean Jacques⁷,Lespessailles Eric⁸,Greenspan Susan L⁹,Bagur Alicia¹⁰,Stepan Jan J¹¹,Lakatos Péter¹²,Casado Enrique¹³,Moericke Rüdiger¹⁴,López-Romero Pedro²,Fahrleitner-Pammer Astrid¹⁵

Affiliation:

1. Maastricht University Medical Center; Maastricht The Netherlands

2. Lilly Research Center Europe; Madrid Spain

3. University of British Columbia; Vancouver Canada

4. CCBR Brasil Centro de Analises e Pesquisas Clínicas; Rio de Janeiro Brazil

5. Centro Paulista de Investigaçao Clínica; Sao Paulo Brazil

6. “Sapienza” Rome University; Rome Italy

7. CHU Brugmann; ULB; Brussels Belgium

8. Regional Hospital of Orléans; Orléans France

9. Osteoporosis Center; University of Pittsburgh; Pittsburgh PA USA

10. Centro de Osteopatías Comlit; Buenos Aires Argentina

11. Institute of Rheumatology and Faculty of Medicine 1; Charles University; Prague Czech Republic

12. Semmelweis University Medical School; Budapest Hungary

13. University Hospital Parc Taulí Sabadell (UAB); Barcelona Spain

14. Institut Präventive Medizin & Klinische Forschung; Magdeburg Germany

15. Division of Endocrinology and Diabetes; Medical University of Graz; Graz Austria

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Reference26 articles.

1. Effects of teriparatide and risedronate on new fractures in postmenopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial;Kendler;Lancet,2018

2. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group;Harris;JAMA,1999

3. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group;Reginster;Osteoporos Int,2000

4. Risedronate prevents new vertebral fractures in postmenopausal women at high risk;Watts;J Clin Endocrinol Metab,2003

5. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group;McClung;N Engl J Med,2001

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sequential management of postmenopausal health and osteoporosis: An update;Maturitas;2023-11

2. Verlaufsdiagnostik des Knochenstoffwechsels unter verschiedenen Therapieformen;Osteologie;2023-10-05

3. Humán rekombináns parathormon (teriparatid) mint alternatív megoldás a gyógyszer okozta állcsontnekrózis terápiájára;Orvosi Hetilap;2023-09-10

4. Osteoporosis management in primary care;The Nurse Practitioner;2023-09

5. Sequential Therapy for the Long-Term Treatment of Postmenopausal Osteoporosis;The Journal of Clinical Endocrinology & Metabolism;2023-08-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3